The glucagon receptor is a protein embedded in the surface of cells, primarily liver cells, that detects the hormone glucagon and translates that signal into action inside the cell. Its best-known job is telling the liver to release stored glucose into the bloodstream when blood sugar drops, but researchers have spent the last two decades uncovering a much broader portfolio: fat metabolism, amino acid processing, energy expenditure, and kidney function all depend on this receptor working properly. It belongs to a family of receptors now at the center of next-generation obesity and diabetes drugs, making it one of the more consequential molecular targets in metabolic medicine.
How the Receptor Is Built
The glucagon receptor, often abbreviated GCGR, is a class B G-protein-coupled receptor. That puts it in a different structural family from many of the receptors you hear about in pharmacology. The receptor threads through the cell membrane seven times, which is standard for this kind of receptor, but its architecture departs from the more common class A type in a couple of ways. It has a large binding pocket for its hormone, and the first membrane-spanning segment extends upward with a stalk-like region that rises above the cell surface. That stalk positions a hefty extracellular domain, roughly 12 kilodaltons, so it can grab onto the glucagon molecule and guide the hormone’s tip down into the transmembrane pocket where signaling gets triggered.1PubMed Central. Structure of the human glucagon class B G-protein-coupled receptor
Scientists resolved the receptor’s full three-dimensional structure relatively recently, using cryo-electron microscopy to capture it bound to glucagon and coupled to the signaling proteins that relay its message inside the cell.2PubMed. Structural basis of Gs and Gi recognition by the human glucagon receptor Having that structural map has been a boon for drug designers, who can now see exactly where small molecules or antibodies might latch on to either boost or block the receptor’s activity.
What Happens When Glucagon Binds
When glucagon docks with its receptor, the receptor changes shape and activates a signaling protein called Gs on the inside of the cell. That kicks off a cascade: an enzyme called adenylate cyclase starts producing a molecule called cAMP, which in turn switches on a kinase known as PKA. PKA then activates transcription factors that flip on the genes needed to make glucose and release it.3PubMed Central. The glucagon receptor is required for the adaptive metabolic response to fasting In cell studies, glucagon binding also causes a transient burst of calcium release inside the cell and activates additional signaling branches that influence cell growth and survival.4PubMed. Glucagon receptor activates extracellular signal-regulated protein kinase 1/2 via cAMP-dependent protein kinase
The receptor does not just fire and stay on indefinitely. After sustained glucagon exposure, the cell pulls the receptor off the surface through a process called internalization. This involves proteins called beta-arrestins and GRK kinases, which tag the receptor for removal via two different routes into the cell interior.5PubMed Central. Dual mode of glucagon receptor internalization: role of PKCα, GRKs and β-arrestins Desensitization prevents the liver from overreacting to a prolonged glucagon spike, but it also means that the receptor’s response is not constant. How long the cAMP signal persists turns out to matter for downstream metabolic effects, and newer research suggests that certain long-acting glucagon variants can sustain that signal by suppressing the enzymes that normally break cAMP down, leading to amplified effects on energy expenditure.6PubMed. Glucagon controls obesity-specific energy expenditure via persistent cAMP/PKA signaling
The Liver and Blood Sugar
The liver is where the glucagon receptor does its most familiar work. Between meals and especially during an overnight fast, falling blood sugar prompts the pancreatic alpha cells to secrete glucagon. Glucagon then binds to its receptor on liver cells and triggers two main processes: glycogenolysis, which breaks down stored glycogen into glucose, and gluconeogenesis, which builds new glucose molecules from scratch using amino acids and other small precursors.3PubMed Central. The glucagon receptor is required for the adaptive metabolic response to fasting The net effect is that glucose pours out of the liver and into the bloodstream, keeping the brain and muscles fueled until the next meal.
This glucose-raising action makes glucagon the mirror image of insulin. Insulin tells the liver to store glucose; glucagon tells it to release glucose. In a healthy person, the two hormones act in a tightly coordinated seesaw. When that coordination breaks down, as it does in type 2 diabetes, the consequences are significant.
When Glucagon Signaling Goes Wrong in Diabetes
In type 2 diabetes, glucagon levels are often inappropriately elevated even when blood sugar is already high, a situation sometimes called hyperglucagonemia. The normal feedback loop, where rising insulin levels from healthy beta cells suppress glucagon release from neighboring alpha cells, weakens as beta-cell function deteriorates. Alpha cells may also become resistant to insulin’s suppressive signal. The result is that the liver keeps pumping out glucose even when it should not, worsening hyperglycemia.7PubMed Central. The role of glucagon on type 2 diabetes at a glance This is why some researchers have argued that type 2 diabetes is as much a disease of glucagon excess as it is of insulin deficiency.
Fat Metabolism in the Liver
Beyond glucose, the glucagon receptor also governs how the liver handles fat. When glucagon signaling is active, hepatic fat oxidation increases, meaning the liver burns more of its stored fat for energy. In diet-induced obese mice, activating the glucagon receptor reduced liver triglyceride content, while blocking the receptor had the opposite effect and allowed fat to accumulate.8PubMed Central. Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice Separate experiments in isolated liver cells confirmed that glucagon receptor signaling ramps up fatty acid oxidation.9PubMed Central. Glucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression
This matters clinically because drugs designed to block the glucagon receptor for blood-sugar control have run into a troubling side effect: increased liver fat. In one trial of the antagonist LY2409021 in people with type 2 diabetes, liver fat content rose significantly compared to both placebo and the comparator drug sitagliptin, alongside increases in liver enzymes, blood pressure, body weight, and cholesterol.10PubMed. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes The pattern makes sense mechanistically: shut off the receptor’s fat-burning signal, and the liver accumulates lipids. This trade-off has been a persistent headache for the antagonist strategy and a key reason why pure glucagon receptor blockers have not made it to market as diabetes drugs.11PubMed Central. Glucagon Receptor Signaling and Lipid Metabolism
Amino Acids and the Liver-Alpha Cell Feedback Loop
One of the more surprising discoveries about the glucagon receptor is its role in amino acid metabolism. Glucagon promotes the breakdown of amino acids in the liver, which feeds into gluconeogenesis (the amino acid skeletons serve as raw material for new glucose). When researchers blocked glucagon receptor signaling, amino acid breakdown in the liver slowed, and amino acid levels in the blood climbed. Those elevated amino acids then acted as growth signals for the pancreatic alpha cells, driving them to multiply. The feedback loop works through a nutrient-sensing pathway involving the growth regulator mTOR: high circulating amino acids activate mTOR in alpha cells, promoting their proliferation.12PubMed. Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass
When mTOR was blocked, the amino-acid-driven alpha cell growth stopped. Even more strikingly, blocking mTOR under these conditions enabled some alpha cells to convert into insulin-producing beta-like cells in living animals.13Cell Reports. Glucagon Signaling Regulates Hepatic Amino Acid Catabolism and Islet Alpha-Cell Proliferation This liver-alpha cell axis has practical implications: any drug that blocks the glucagon receptor will likely cause alpha cell overgrowth, which is exactly what has been observed in both animal models and human trials of glucagon receptor antagonists. The effect is not merely cosmetic; unchecked alpha cell expansion raises glucagon levels further, partially undoing the therapeutic benefit.
Energy Expenditure and Body Heat
Glucagon has long been known to boost metabolic rate. In a human study, a glucagon infusion raised resting metabolic rate by about 15% above baseline, a bump comparable to what cold exposure achieved in the same volunteers. Interestingly, this increase in energy expenditure occurred even in people whose brown adipose tissue showed no significant activation during glucagon infusion, indicating that glucagon raises metabolic rate through pathways that do not depend on brown fat.14PubMed Central. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
That said, the glucagon receptor does exist on brown fat cells, and glucagon exposure turns on thermogenic genes in those cells in laboratory settings. Mice engineered to lack all proglucagon-derived peptides struggled to maintain body temperature in the cold and showed reduced thermogenic gene expression in brown fat. Giving them glucagon restored the expression of the key heat-generating protein UCP1 and improved their cold tolerance, apparently by boosting production of the hormone FGF21 in the liver.15Endocrinology. Glucagon Is Essential for Adaptive Thermogenesis in Brown Adipose Tissue However, when only the brown-fat glucagon receptor was knocked out, leaving the liver and other tissues intact, the mice maintained normal body weight, temperature, and energy expenditure, even on a high-fat diet or in the cold.16PubMed Central. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice The emerging picture is that glucagon’s energy-boosting effect operates mainly through the liver and possibly the brain, with brown fat playing a supporting but dispensable role.
Beyond the Liver
While the liver has the densest concentration of glucagon receptors, the receptor appears in several other tissues, and its roles outside the liver are still being mapped.
In the kidney, the glucagon receptor sits on the tubular cells of the nephron. When researchers knocked it out specifically in adult mouse kidneys, the animals developed features resembling chronic kidney disease: oxidative stress, inflammation, excess lipid buildup in the kidney, and reduced kidney glucose output. These mice also had elevated amino acid levels in their blood, echoing the liver-alpha cell axis described above but originating from the kidney’s own metabolic machinery.17PubMed Central. Downregulation of the kidney glucagon receptor, essential for renal function and systemic homeostasis, contributes to chronic kidney disease In human kidney disease, glucagon receptor expression is reduced, raising the possibility that loss of renal glucagon signaling contributes to disease progression rather than merely being a consequence of it.
The heart is a more ambiguous case. High doses of glucagon clearly have cardiovascular effects, raising heart rate, increasing the force of the heart’s contractions, and elevating blood pressure. Emergency medicine has used injectable glucagon for decades as a treatment for beta-blocker overdose, precisely because of these effects. Yet whether the human heart actually expresses the glucagon receptor in meaningful quantities remains unclear. A recent review noted that unequivocal evidence for cardiac glucagon receptor expression in humans is still lacking, meaning that glucagon’s heart effects might be mediated indirectly through other pathways rather than through a receptor sitting on heart cells themselves.18PubMed. Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists
What Happens When the Receptor Is Completely Lost
A rare genetic condition called Mahvash disease (also known as glucagon cell hyperplasia and neoplasia) illustrates what life looks like without a working glucagon receptor. People with Mahvash disease carry inactivating mutations on both copies of the GCGR gene, leaving their cells unable to respond to glucagon at all. Without the receptor’s feedback signal, alpha cells receive constant “grow” signals from rising amino acids and secrete enormous amounts of glucagon that the body cannot use. The alpha cells expand massively, and over time can progress from hyperplasia to pancreatic neuroendocrine tumors and occasionally to malignant, metastatic disease.19The Journal of Clinical Endocrinology & Metabolism. Hypercalcemia in Glucagon Cell Hyperplasia and Neoplasia (Mahvash Syndrome)
Because the receptor is nonfunctional, these patients do not show the classic symptoms you would expect from a glucagon-producing tumor: no skin rash (necrolytic migratory erythema) and no hyperglycemia. They may actually experience low blood sugar. The condition is autosomal recessive, meaning you need both copies knocked out for full disease. However, a recent case series found that heterozygous carriers, people with one working and one broken copy, can show mild biochemical abnormalities like elevated glucagon levels and small pancreatic cysts, even without overt tumors.20PubMed Central. Challenging the recessive paradigm of Mahvash disease: heterozygous phenotypes from a novel splice-site variant The condition has historically been identified only in adults, but at least one pediatric case was caught through newborn screening that flagged elevated arginine, one of the amino acids that rises when the receptor is absent.21PubMed Central. The first pediatric case of glucagon receptor defect due to biallelic mutations in GCGR is identified by newborn screening of elevated arginine
Drugs That Target the Glucagon Receptor
The receptor’s involvement in blood sugar, fat, and body weight has made it an attractive drug target from multiple angles.
On the agonist side, glucagon itself has been a standard rescue treatment for severe hypoglycemia for decades. Newer formulations, including a nasal spray and a ready-to-use liquid pen, have replaced the older kits that required reconstitution. Clinical comparisons show that these modern delivery methods are equally effective, with nearly all treated patients recovering from insulin-induced low blood sugar.22Diabetes. Indirect Treatment Comparison of Ready-to-Use Glucagon Rescue Treatments for Severe Hypoglycemia
Pure antagonists aimed at lowering blood sugar in diabetes have had a bumpier road. The small-molecule antagonist LY2409021 lowered fasting glucose in people with type 2 diabetes, with reductions up to roughly 1.25 mmol/l after four weeks.23PubMed. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes But the liver fat and liver enzyme increases that surfaced in longer trials have stalled the pure-antagonist approach. An antibody antagonist called volagidemab, tested in type 1 diabetes as an add-on to insulin, reduced HbA1c by about half a percentage point more than placebo and did not increase hypoglycemia, but it too raised LDL cholesterol, liver enzymes, and blood pressure.24PubMed Central. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
The Multi-Agonist Strategy
Rather than blocking the glucagon receptor entirely, the most exciting therapeutic direction right now is combining partial glucagon receptor activation with activation of related receptors, particularly the GLP-1 receptor and the GIP receptor, in a single molecule. The logic is that the GLP-1 component suppresses appetite and lowers blood sugar, while the glucagon component ramps up energy expenditure and fat burning. Done right, the glucagon arm burns extra calories without causing the dangerous blood sugar spikes it would cause alone, because the GLP-1 arm keeps glucose in check.
A dual GLP-1/glucagon agonist called MEDI0382 demonstrated this principle in mice: it produced greater weight loss than the GLP-1-only drug liraglutide at comparable doses, with the additional fat loss attributed to glucagon-receptor-mediated increases in energy expenditure while appetite suppression came from the GLP-1 side.25PubMed Central. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
The approach has been pushed further with triple agonists that activate the GLP-1, GIP, and glucagon receptors simultaneously. Retatrutide, the most advanced of these, produced remarkable weight loss in a phase 2 trial: adults with obesity lost an average of about 24% of their body weight at the highest dose over 48 weeks, compared to about 2% with placebo.26PubMed. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial In people with type 2 diabetes, the same drug lowered HbA1c by up to 2 percentage points more than placebo and produced bodyweight reductions of nearly 17% at 36 weeks at the highest dose.27The Lancet. Retatrutide, a single peptide with glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonist activity, in people with type 2 diabetes Phase 3 trials are underway. The glucagon receptor arm of these triple agonists is a major reason the weight loss numbers are as large as they are, since the earlier dual GIP/GLP-1 agonist tirzepatide, which lacks glucagon receptor activity, already showed substantial weight loss but did not reach the same magnitude at equivalent time points.
An Ancient Receptor Family
The glucagon receptor is not a recent evolutionary invention. Phylogenetic analyses show that the glucagon receptor family, which includes the receptors for GLP-1, GLP-2, and GIP, shares high sequence similarity across all vertebrates, from fish to mammals.28PubMed Central. Evolution of GCGR family ligand‒receptor extensive cross-interaction systems suggests a therapeutic direction for hyperglycemia in mammals The family’s roots go back even further: functional homologs of the glucagon/PACAP receptor system have been identified in amphioxus, an invertebrate chordate that diverged from the vertebrate lineage over 500 million years ago.29Molecular Biology and Evolution. Functional Pairing of Class B1 Ligand-GPCR in Cephalochordate Provides Evidence of the Origin of PTH and PACAP/Glucagon Receptor Family The deep conservation of this system speaks to how fundamental the problem it solves really is: every animal that moves between fed and fasted states needs a reliable way to mobilize stored fuel, and the glucagon receptor family has been doing that job since before vertebrates had bones.
Imaging the Receptor in Living People
One practical challenge with the glucagon receptor is that you cannot easily see how much of it a patient has in a given organ, or whether a drug is actually occupying it. That gap is starting to close. Researchers have developed the first PET imaging tracer specifically designed to bind the glucagon receptor, a gallium-68-labeled glucagon analog. In preclinical testing, this tracer showed the properties needed for clinical use, including specificity for the receptor and suitable pharmacokinetics. If it makes it through human validation, it could allow physicians to directly measure glucagon receptor density in a patient’s liver or other organs and assess how much of the receptor a therapeutic drug is blocking or activating.30PubMed Central. First-in-class positron emission tomography tracer for the glucagon receptor That kind of quantitative imaging could be particularly useful for fine-tuning doses of the multi-agonist drugs now in clinical trials, where getting the right balance of glucagon receptor activation is the difference between burning fat and spiking blood sugar.